Healthpeak Properties, Inc. (DOC) Stock Analysis and Metrics

Healthpeak Properties

NYSE: DOC

$22.27 ▲ +0.19 (+0.86%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap15.34 Bn

P/E69.22

P/S-33.80

Div. Yield0.06

ROIC (Qtr)0.00

Total Debt (Qtr)246.46 Mn

Add ratio to table…

About

Healthpeak Properties Inc is a real estate investment trust that owns operates and develops healthcare focused real estate across the United States. The company was founded in 1985 and is organized as an umbrella partnership REIT known as an UPREIT. It holds substantially all of its assets and conducts operations through its operating subsidiary Healthpeak OP. Healthpeak Properties Inc qualifies as a self administered REIT and is headquartered in Denver Colorado with additional corporate offices in California Tennessee Wisconsin and Massachusetts and property management offices in numerous locations nationwide. The firm concentrates on three core asset classes outpatient medical buildings laboratory facilities and senior housing communities. It seeks to provide high quality property assets that support healthcare delivery innovation and the evolving needs of patients providers and researchers.

Healthpeak Properties Inc generates revenue primarily through leasing its real estate portfolio to tenants under long term agreements. The company collects rental income from outpatient medical buildings leased to physicians and hospital systems from laboratory spaces leased to biotechnology pharmaceutical and medical device firms and from senior housing properties operated under RIDEA structures where third party managers pay fees for property use. Additional income may arise from property sales financing interest and joint venture distributions. The majority of revenue comes from triple net leases where tenants cover property taxes insurance and maintenance costs. Healthpeak Properties Inc also earns fees from property management services and may realize gains from the disposition of non core assets. Its revenue streams are supported by long term leases that provide predictable cash flow and by opportunities to adjust rents in line with market conditions and tenant improvements.

The company operates through the following reportable segments: Outpatient medical Lab and Senior housing. These segments are defined based on the nature of the properties and the type of tenants they serve and are used by the chief operating decision maker to assess performance and allocate resources. Other activities such as loans receivable and preferred equity investments are presented in a combined non reportable category.

• Outpatient medical includes outpatient medical buildings and hospitals that lease space to physicians hospital systems and related healthcare providers offering services such as diagnostic centers rehabilitation clinics and day surgery operating rooms often located on or adjacent to hospital campuses. Approximately seventy nine percent of the outpatient medical square footage is situated on or next to hospital campuses and about ninety six percent is affiliated with hospital systems. Lease structures in this segment are predominantly triple net with roughly seventy two percent of the space under triple net arrangements and the remainder under gross or modified gross agreements. The segment benefits from stable demand for outpatient care and the ongoing expansion of hospital affiliated practices.

• Lab consists of laboratory and office space leased to biotechnology pharmaceutical medical device companies research institutions and government agencies featuring advanced electrical mechanical and HVAC systems to support specialized equipment such as fume hoods and lab benches primarily situated in established research clusters like San Francisco Boston and San Diego. About eighty nine percent of the laboratory square footage is under triple net leases. The properties are often configured in business park or campus settings allowing contiguous expansion for tenants needing additional space. Location choices reflect proximity to major research universities and life science hubs that attract sustained investment in scientific discovery.

• Senior housing comprises life plan communities and an interest in a joint venture with a sovereign wealth fund providing independent living assisted living memory care and skilled nursing units operated through RIDEA structures where third party managers handle day to day operations and the company receives cash flow via a taxable REIT subsidiary. Life plan communities offer a continuum of care on a single campus enabling residents to age in place with access to independent living assisted living memory care and skilled nursing services. The joint venture interests include properties that serve similar senior populations and are also managed under RIDEA agreements. Revenue in this segment is derived from resident fees and management fee arrangements rather than traditional triple net leases.

Healthpeak Properties Inc holds a leading position among healthcare real estate investment trusts with a diversified portfolio that balances exposure to outpatient medical laboratory and senior housing assets. The company competes with other REITs private equity firms pension funds and institutional investors that pursue similar healthcare property opportunities. Its competitive advantages stem from long term relationships with major health systems a strong investment grade balance sheet and a proven ability to acquire develop and manage high quality properties in desirable locations. Additionally Healthpeak Benefits from a scalable internal platform that integrates property management leasing and capital allocation functions. The firm's focus on sectors driven by demographic trends such as aging populations and increasing demand for outpatient and laboratory services further strengthens its market position.

Healthpeak Properties Inc serves a varied customer base that includes hospital systems such as HCA Healthcare Inc and CommonSpirit Health physician groups biotechnology and pharmaceutical companies scientific research institutions government agencies and senior housing residents through third party operators. The company's tenants range from large national health care providers to specialized life science firms and older adults seeking independent or assisted living arrangements. In the outpatient medical segment notable tenants include major health care operators that lease significant square footage across multiple markets. In the laboratory segment tenants encompass leading biotech firms engaged in drug discovery and medical device manufacturers conducting research and development. In the senior housing segment residents are served by third party operator companies that provide daily care and support services under contractual agreements. This diverse tenant mix helps to reduce reliance on any single industry and supports steady occupancy across the portfolio.

Investment Thesis

▲ Bull case

Healthpeak Properties (DOC) is positioned to benefit from a structural inflection point in the life sciences real estate sector, where its concentrated portfolio in high-barrier submarkets—particularly South San Francisco’s Gateway campus—provides an asymmetric advantage as biopharma capital raising rebounds. The company’s early 2026 acquisition of the Gateway campus at a fraction of replacement cost has already generated 62,000 square feet of signed leases and letters of intent, with an additional 113,000 square feet in active proposals, signaling leasing momentum that exceeds initial underwriting assumptions. This is not a temporary cyclical bounce but a reflection of durable demand from venture-backed biotech and large-cap pharma tenants seeking move-in-ready, well-located lab space, a niche Healthpeak dominates due to its decades-long relationships and in-house operating platform that minimizes leasing costs to just over $1 per square foot per year in renewals—far below peer averages. The company’s ability to achieve 5.4% cash re-leasing spreads on renewals with minimal tenant improvements, coupled with 3% annual escalators embedded in leases for over five years, creates a compounding effect on same-store NOI growth that has averaged 3.5% over the past half-decade—30% above its prior five-year average. This operational efficiency, validated by the Baylor Scott & White cancer center renewal where leasing costs were negligible, allows Healthpeak to convert occupancy gains directly into earnings without proportional cost increases, a dynamic the market is underestimating as it focuses on headline vacancy rates rather than the quality and economics of leased space.
The IPO of Janus Living represents a transformative capital recycling strategy that is generating multiple arbitrage value far beyond what is reflected in Healthpeak’s current stock price. By selling 18% of its senior housing business while simultaneously deploying over $700 million in pre-IPO acquisitions to maintain economic exposure, Healthpeak locked in a valuation uplift where the $240 million of current-year FFO from the senior housing portfolio is now valued at a multiple roughly 20 turns higher than Healthpeak’s own trading multiple. This discrepancy is not merely an accounting artifact but a tangible pathway to earnings accretion: the IPO proceeds are expected to generate $0.04 per share in accretive earnings once fully invested and stabilized, with the company already deploying capital into accretive senior housing acquisitions at a cost of structure that benefits the 82%-owned Janus Living entity. Furthermore, the Blackstone joint venture recap on a fully occupied outpatient portfolio at a 6.1% cash cap rate—200 basis points below the implied cap rate in Healthpeak’s stock price—provides a scalable template for future transactions, with additional deals targeting $700 million or more in proceeds at similarly attractive spreads. The April $100 million stock buyback at over 10% FFO yield, combined with a 7.5% annualized dividend yield supported by a solid payout ratio, underscores management’s conviction that the stock is deeply mispriced relative to intrinsic value, and their disciplined approach to leverage-neutral capital return will continue to drive earnings per share growth even as external observers fixate on near-term occupancy metrics.
Healthpeak’s outpatient medical platform is experiencing a quiet but powerful renaissance driven by long-term contractual relationships and operational excellence that is being richly rewarded in private market transactions. Since the Physicians merger three years ago, the company has renewed over 10 million square feet at cash re-leasing spreads of positive 5.8%, with half of renewals completed in-house to save $5 million in leasing commissions last quarter alone—demonstrating a structural cost advantage that persists even as market rents stabilize. The ability to secure 3% annual escalators on both new leases and renewals for five consecutive years, combined with tenant retention rates of 79% and minimal leasing costs at just 10% of annual rents, creates a durable cash flow engine that is largely insulated from macroeconomic volatility. This is not dependent on speculative development but on the optimization of a high-quality, second-generation asset base where tenants like Baylor Scott & White, Norton Health, and HCA are choosing to renew long-term leases—such as the 10-year, 458,000-square-foot campus in Dallas—based on trust and service quality rather than pure price competition. The market is overlooking how this platform’s stability and cash flow predictability provide a reliable foundation to fund growth in higher-beta segments like life sciences, while simultaneously generating excess capital for shareholder returns through buybacks and dividends, a dual-engine model that is underappreciated in current valuations.

Healthpeak Properties (DOC) is positioned to benefit from a structural inflection point in the life sciences real estate sector, where its concentrated portfolio in high-barrier submarkets—particularly South San Francisco’s Gateway campus—provides an asymmetric advantage as biopharma capital raising rebounds. The company’s early 2026 acquisition of the Gateway campus at a fraction of replacement cost has already generated 62,000 square feet of signed leases and letters of intent, with an additional 113,000 square feet in active proposals, signaling leasing momentum that exceeds initial underwriting assumptions. This is not a temporary cyclical bounce but a reflection of durable demand from venture-backed biotech and large-cap pharma tenants seeking move-in-ready, well-located lab space, a niche Healthpeak dominates due to its decades-long relationships and in-house operating platform that minimizes leasing costs to just over $1 per square foot per year in renewals—far below peer averages. The company’s ability to achieve 5.4% cash re-leasing spreads on renewals with minimal tenant improvements, coupled with 3% annual escalators embedded in leases for over five years, creates a compounding effect on same-store NOI growth that has averaged 3.5% over the past half-decade—30% above its prior five-year average. This operational efficiency, validated by the Baylor Scott & White cancer center renewal where leasing costs were negligible, allows Healthpeak to convert occupancy gains directly into earnings without proportional cost increases, a dynamic the market is underestimating as it focuses on headline vacancy rates rather than the quality and economics of leased space.
The IPO of Janus Living represents a transformative capital recycling strategy that is generating multiple arbitrage value far beyond what is reflected in Healthpeak’s current stock price. By selling 18% of its senior housing business while simultaneously deploying over $700 million in pre-IPO acquisitions to maintain economic exposure, Healthpeak locked in a valuation uplift where the $240 million of current-year FFO from the senior housing portfolio is now valued at a multiple roughly 20 turns higher than Healthpeak’s own trading multiple. This discrepancy is not merely an accounting artifact but a tangible pathway to earnings accretion: the IPO proceeds are expected to generate $0.04 per share in accretive earnings once fully invested and stabilized, with the company already deploying capital into accretive senior housing acquisitions at a cost of structure that benefits the 82%-owned Janus Living entity. Furthermore, the Blackstone joint venture recap on a fully occupied outpatient portfolio at a 6.1% cash cap rate—200 basis points below the implied cap rate in Healthpeak’s stock price—provides a scalable template for future transactions, with additional deals targeting $700 million or more in proceeds at similarly attractive spreads. The April $100 million stock buyback at over 10% FFO yield, combined with a 7.5% annualized dividend yield supported by a solid payout ratio, underscores management’s conviction that the stock is deeply mispriced relative to intrinsic value, and their disciplined approach to leverage-neutral capital return will continue to drive earnings per share growth even as external observers fixate on near-term occupancy metrics.
Healthpeak’s outpatient medical platform is experiencing a quiet but powerful renaissance driven by long-term contractual relationships and operational excellence that is being richly rewarded in private market transactions. Since the Physicians merger three years ago, the company has renewed over 10 million square feet at cash re-leasing spreads of positive 5.8%, with half of renewals completed in-house to save $5 million in leasing commissions last quarter alone—demonstrating a structural cost advantage that persists even as market rents stabilize. The ability to secure 3% annual escalators on both new leases and renewals for five consecutive years, combined with tenant retention rates of 79% and minimal leasing costs at just 10% of annual rents, creates a durable cash flow engine that is largely insulated from macroeconomic volatility. This is not dependent on speculative development but on the optimization of a high-quality, second-generation asset base where tenants like Baylor Scott & White, Norton Health, and HCA are choosing to renew long-term leases—such as the 10-year, 458,000-square-foot campus in Dallas—based on trust and service quality rather than pure price competition. The market is overlooking how this platform’s stability and cash flow predictability provide a reliable foundation to fund growth in higher-beta segments like life sciences, while simultaneously generating excess capital for shareholder returns through buybacks and dividends, a dual-engine model that is underappreciated in current valuations.

▼ Bear case

Healthpeak Properties (DOC) faces significant near-term headwinds in its life science segment that are being masked by optimistic commentary on pipeline activity, as the company’s occupancy growth guidance of merely 100 basis points by year-end 2026 reveals a painfully slow recovery trajectory despite favorable macro conditions. While management highlights increased leasing activity and strong demand in South San Francisco, the portfolio remains at only 77.7% total occupancy as of Q1 2026—meaning over one-fifth of its life science space is still vacant—and the pace of absorption is so gradual that it relies on the assumption that 400,000 square feet of expirations in 2026 will be nearly offset by just over 500,000 square feet of commencements, leaving minimal room for error. This sluggish pace is exacerbated by the company’s own admission that 50,000 square feet of known vacates are expected in Q2 and Q3 2026 from two specific tenants, a drag that could easily erase any modest occupancy gains if leasing momentum falters. The reliance on “move-in-ready” space preferences—while beneficial for reducing tenant improvement costs—also indicates that Healthpeak’s portfolio may lack the flexibility to attract tenants requiring significant build-outs, limiting its ability to capture demand from emerging biotech firms that often need customized wet lab configurations, thereby constraining the upside potential of its pipeline despite optimistic commentary on M&A and capital raising trends in the sector.
The financial engineering surrounding the Janus Living IPO introduces material earnings volatility and execution risk that is being understated in management’s neutral-to-accretive narrative, particularly due to the timing mismatch between capital deployment and earnings recognition. Although Healthpeak claims the IPO will be earnings neutral in 2026 and accretive thereafter, this hinges on the successful deployment of $750 million in cash proceeds into acquisitions through year-end—a target that is already behind schedule given that only $270 million of proceeds have been received to date, with the remainder contingent on future recapitalizations and seller financing repayments that are inherently uncertain and subject to market conditions. Furthermore, the company incurred incremental public company costs and faces a temporary earnings drag from holding non-productive cash on the balance sheet, which management admits will offset the senior housing portfolio’s outperformance in the near term. The assertion that the IPO created “enormous value” ignores the dilution effect of selling 18% of a high-growth business while simultaneously relying on the success of acquisitions made *prior* to the IPO to maintain exposure—a strategy that worked only because of fortunate timing in Q1 2026, not a repeatable model. If the senior housing segment fails to maintain its exceptional 35% revenue growth and 42% adjusted EBITDA growth from Q1 2026, the entire accretion thesis collapses, leaving Healthpeak exposed to the dual burden of a diluted ownership stake in Janus Living and the opportunity cost of capital tied up in a non-core platform.
Healthpeak’s outpatient medical segment, while appearing strong on surface metrics, is increasingly vulnerable to structural shifts in healthcare delivery that could erode its long-term lease durability and re-leasing spreads, a risk that is being ignored due to backward-looking performance praise. The company’s reliance on large health system partners like Baylor Scott & White, HCA, and Norton Health—whose renewals drive the bulk of its 5.8% average re-leasing spreads—creates concentration risk, as these entities are simultaneously under pressure to consolidate outpatient services, shift care to lower-cost settings, and negotiate aggressively on real estate expenses amid margin compression from value-based care models and rising labor costs. The touted 3% annual escalators, while historically reliable, may become unsustainable if tenants begin to push back on rent increases in response to declining reimbursement rates or increased competition from ambulatory surgery centers and retail clinics, particularly in markets where Healthpeak’s concentration strategy limits its ability to leverage alternative tenants. Moreover, the emphasis on minimizing leasing costs and tenant improvements—while beneficial for short-term cash flow—may signal an unwillingness to invest in property upgrades or amenities that could be necessary to retain tenants as healthcare consumer preferences evolve toward more integrated, experience-driven outpatient environments, leaving the portfolio vulnerable to gradual obsolescence despite its current high occupancy and strong renewal rates.

Healthpeak Properties (DOC) faces significant near-term headwinds in its life science segment that are being masked by optimistic commentary on pipeline activity, as the company’s occupancy growth guidance of merely 100 basis points by year-end 2026 reveals a painfully slow recovery trajectory despite favorable macro conditions. While management highlights increased leasing activity and strong demand in South San Francisco, the portfolio remains at only 77.7% total occupancy as of Q1 2026—meaning over one-fifth of its life science space is still vacant—and the pace of absorption is so gradual that it relies on the assumption that 400,000 square feet of expirations in 2026 will be nearly offset by just over 500,000 square feet of commencements, leaving minimal room for error. This sluggish pace is exacerbated by the company’s own admission that 50,000 square feet of known vacates are expected in Q2 and Q3 2026 from two specific tenants, a drag that could easily erase any modest occupancy gains if leasing momentum falters. The reliance on “move-in-ready” space preferences—while beneficial for reducing tenant improvement costs—also indicates that Healthpeak’s portfolio may lack the flexibility to attract tenants requiring significant build-outs, limiting its ability to capture demand from emerging biotech firms that often need customized wet lab configurations, thereby constraining the upside potential of its pipeline despite optimistic commentary on M&A and capital raising trends in the sector.
The financial engineering surrounding the Janus Living IPO introduces material earnings volatility and execution risk that is being understated in management’s neutral-to-accretive narrative, particularly due to the timing mismatch between capital deployment and earnings recognition. Although Healthpeak claims the IPO will be earnings neutral in 2026 and accretive thereafter, this hinges on the successful deployment of $750 million in cash proceeds into acquisitions through year-end—a target that is already behind schedule given that only $270 million of proceeds have been received to date, with the remainder contingent on future recapitalizations and seller financing repayments that are inherently uncertain and subject to market conditions. Furthermore, the company incurred incremental public company costs and faces a temporary earnings drag from holding non-productive cash on the balance sheet, which management admits will offset the senior housing portfolio’s outperformance in the near term. The assertion that the IPO created “enormous value” ignores the dilution effect of selling 18% of a high-growth business while simultaneously relying on the success of acquisitions made *prior* to the IPO to maintain exposure—a strategy that worked only because of fortunate timing in Q1 2026, not a repeatable model. If the senior housing segment fails to maintain its exceptional 35% revenue growth and 42% adjusted EBITDA growth from Q1 2026, the entire accretion thesis collapses, leaving Healthpeak exposed to the dual burden of a diluted ownership stake in Janus Living and the opportunity cost of capital tied up in a non-core platform.
Healthpeak’s outpatient medical segment, while appearing strong on surface metrics, is increasingly vulnerable to structural shifts in healthcare delivery that could erode its long-term lease durability and re-leasing spreads, a risk that is being ignored due to backward-looking performance praise. The company’s reliance on large health system partners like Baylor Scott & White, HCA, and Norton Health—whose renewals drive the bulk of its 5.8% average re-leasing spreads—creates concentration risk, as these entities are simultaneously under pressure to consolidate outpatient services, shift care to lower-cost settings, and negotiate aggressively on real estate expenses amid margin compression from value-based care models and rising labor costs. The touted 3% annual escalators, while historically reliable, may become unsustainable if tenants begin to push back on rent increases in response to declining reimbursement rates or increased competition from ambulatory surgery centers and retail clinics, particularly in markets where Healthpeak’s concentration strategy limits its ability to leverage alternative tenants. Moreover, the emphasis on minimizing leasing costs and tenant improvements—while beneficial for short-term cash flow—may signal an unwillingness to invest in property upgrades or amenities that could be necessary to retain tenants as healthcare consumer preferences evolve toward more integrated, experience-driven outpatient environments, leaving the portfolio vulnerable to gradual obsolescence despite its current high occupancy and strong renewal rates.

Segments Breakdown of Revenue (2023)

Peer Comparison

Companies in the REIT - Healthcare Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WELL	Welltower Inc.	172.91 Bn	122.84	12.78	17.93 Bn
2	VTR	Ventas, Inc.	46.62 Bn	179.03	7.60	-
3	DOC	Healthpeak Properties, Inc.	15.34 Bn	69.22	-33.80	0.25 Bn
4	OHI	Omega Healthcare Investors Inc	15.14 Bn	23.22	12.25	0.43 Bn
5	AHR	American Healthcare REIT, Inc.	10.71 Bn	194.58	4.76	1.51 Bn
6	CTRE	CareTrust REIT, Inc.	9.45 Bn	28.24	199.40	0.50 Bn
7	HR	Healthcare Realty Trust Inc	7.33 Bn	-	5.04	4.10 Bn
8	SBRA	Sabra Health Care REIT, Inc.	5.09 Bn	36.93	17.13	0.04 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2023)

Segments Breakdown of Revenue (2023)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2023)

Segments Breakdown of Revenue (2023)

Peer Comparison

Create an account

Sign In

Reset Password